二缩甘露醇一油酸 | 25339-93-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 二缩甘露醇一油酸
• 英文名称: Mannide monooleate
• 英文别名: [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate
• CAS: 25339-93-9
• 化学式: C₂₄H₄₄O₇
• 分子量: 444.6
• InChiKey: LUXUAZKGQZPOBZ-SAXJAHGMSA-N

物化性质

• 沸点：
  100 °C
• 密度：
  0.97
• 物理描述：
  Mannide monooleate is a clear yellow to brown liquid. (NTP, 1992)
• 闪点：
  greater than 212 °F (NTP, 1992)
• 溶解度：
  50 to 100 mg/mL at 68° F (NTP, 1992)
• 稳定性/保质期：
  <p>遵照规定使用和储存，则不会分解。</p>

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  31
• 可旋转键数：
  18
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  7

SDS

Name:	Arlacel A Material Safety Data Sheet
Synonym:
CAS:	25339-93-9

Section 1 - Chemical Product MSDS Name:Arlacel A Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
25339-93-9	Arlacel A		246-872-8

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 25339-93-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: clear yellow to brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: 275-350 cP 25 deg
Boiling Point: > 100 deg C
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: > 149 deg C (> 300.20 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: Not available.
Specific Gravity/Density: .9700g/cm3
Molecular Formula:
Molecular Weight: 412.61

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Not available.
Incompatibilities with Other Materials:
Not available.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 25339-93-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Arlacel A - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 25339-93-9: 1
Canada
CAS# 25339-93-9 is listed on Canada's DSL List.
CAS# 25339-93-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 25339-93-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

文献信息

• [EN] METHODS AND COMPOSITIONS FOR SUBSTANCE USE DISORDER VACCINE FORMULATIONS AND USES THEREOF<br/>[FR] MÉTHODES ET COMPOSITIONS DESTINÉES À DES FORMULATIONS VACCINALES CONTRE DES TROUBLES LIÉS À UNE SUBSTANCE, ET LEURS UTILISATIONS
  申请人：MOLECULAR EXPRESS INC

  公开号：WO2018231706A1

  公开（公告）日：2018-12-20

  The present invention relates to vaccine compositions for treatment of substance use disorders, methods for the manufacture thereof, and methods for the use thereof to treat an animal. These compositions comprise a hapten conjugated via a linker to a protein scaffold and mixed with a particulate carrier and at least one immunostimulatory adjuvant molecule.

  本发明涉及用于治疗物质使用障碍的疫苗组合物，其制造方法以及用于治疗动物的方法。这些组合物包括通过连接剂与蛋白质支架结合的半抗原，并与颗粒载体和至少一种免疫刺激性佐剂分子混合。
• Substituted phenyl naphthalenes as estrogenic agents
  申请人：Wyeth

  公开号：US20030181519A1

  公开（公告）日：2003-09-25

  This invention provides estrogen receptor modulators of formula I, having the structure 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 , are as defined in the specification, or a pharmaceutically acceptable salt thereof.

  这项发明提供了具有结构的式I的雌激素受体调节剂 1 其中 R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 ，R 8 ，R 9 和R 10 如规范中所定义，或其药用可接受盐。
• [EN] CANCER VACCINE<br/>[FR] VACCIN ANTI-CANCER
  申请人：VICTORIA LINK LTD

  公开号：WO2021045632A1

  公开（公告）日：2021-03-11

  The invention relates to a combination of a TLR-9 agonist and a conjugate of Formula (I) or pharmaceutically acceptable salt thereof. (Formula (I))

  本发明涉及TLR-9激动剂与式(I)的偶联物或其药物可接受的盐的联合使用。 (式(I))
• NUCLEIC ACID DERIVATIVE HAVING IMMUNOSTIMULATORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：US20180264105A1

  公开（公告）日：2018-09-20

  The purpose of the present invention is to provide double-stranded oligonucleotides comprising the CpG oligonucleotide mentioned below, as a nucleic acid derivative having an immunostimulatory activity. An adjuvant comprising a double-stranded oligonucleotide, wherein a first strand is a CpG oligonucleotide consisting of 8 to 50 nucleotides, a second strand is an oligonucleotide consisting of 8 to 60 nucleotides and comprising a sequence capable of hybridizing with the first strand, and a lipid binds to the second strand through a linker.

  本发明的目的是提供包含如下所述CpG寡核苷酸的双链寡核苷酸，作为一种具有免疫刺激活性的核酸衍生物。 一种包含双链寡核苷酸的佐剂，其中 第一链是由8到50个核苷酸组成的CpG寡核苷酸， 第二链是由8到60个核苷酸组成的寡核苷酸，并且包括 能够与第一链杂交的序列，以及通过连接器与第二链结合的脂质。
• [EN] MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG<br/>[FR] MANNOSIDES MULTIMÉRIQUES, UN PROCÉDÉ DE PRÉPARATION DE CEUX-CI ET LEURS UTILISATIONS EN TANT QUE MÉDICAMENT
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2014016361A1

  公开（公告）日：2014-01-30

  The present invention relates to multimeric mannosides, a process for preparing the same and their uses in medicine for treating Escherichia Coli infections. Exemplary compounds are:

  本发明涉及多聚甘露糖苷，其制备方法以及它们在医药中用于治疗大肠杆菌感染的用途。典型的化合物包括：